Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
18–100
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult patients with advanced (metastatic or unresectable) KRAS G12C mutant solid tumors who have received standard of care or are intolerant or ineligible to approved therapies
ECOG Performance Status of 0 or 1
At least one measurable lesion as defined by RECIST 1.1
Prior treatment with a KRAS G12C inhibitor may be allowed for dose escalations of combinations and a subset of groups in dose expansion
You may not be if
Tumors harboring driver mutations that have approved targeted therapies, with the exception of KRAS G12C mutations
Symptomatic brain metastases or known leptomeningeal disease. Patients with asymptomatic treated or untreated brain metastases may be eligible
Clinically significant cardiac disease or risk factors at screening
Clareo Health | Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
